• Something wrong with this record ?

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial

BA. Bergmark, ML. O'Donoghue, SA. Murphy, JF. Kuder, MV. Ezhov, R. Ceška, I. Gouni-Berthold, HK. Jensen, SL. Tokgozoglu, F. Mach, K. Huber, Z. Gaciong, BS. Lewis, F. Schiele, JW. Jukema, TR. Pedersen, RP. Giugliano, MS. Sabatine

. 2020 ; 5 (6) : 709-713. [pub] 20200601

Language English Country United States

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21012543

Importance: Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a life-threatening condition with no proven disease-modifying therapy. Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) have been implicated in the pathobiology of AS. The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab reduces circulating LDL-C concentrations by 50% to 60% and Lp(a) by 20% to 30%. Objective: To determine whether evolocumab reduces the risk of AS events in patients with atherosclerotic cardiovascular disease. Interventions: Patients were randomized 1:1 to evolocumab or placebo. Design, Setting, and Participants: Exploratory analysis of the FOURIER trial, which enrolled 27 564 patients with stable atherosclerotic cardiovascular disease who were taking statin therapy at 1242 sites in 49 countries from February 2013 to November 2016. Patients were randomized to evolocumab or placebo and followed up for a median (interquartile range) of 2.2 (1.8-2.5) years. This post hoc analysis was performed from September 2019 to February 2020. Main Outcomes and Measures: Site-reported adverse events of new or worsening AS or aortic valve replacement (termed AS events). The adjusted risk of AS events was calculated with a multivariable model including concentrations of Lp(a) and LDL-C corrected for Lp(a) content, plus age, sex, diabetes, hypertension, current smoking, and estimated glomerular filtration rate. Evolocumab efficacy was tested using a Cox proportional hazards model. Results: Aortic stenosis events occurred in 63 patients (48 men [76%]; mean [SD] age, 69 [9] years) over a median of 2.2 years. Elevated Lp(a) concentration was associated with higher rates of AS events (adjusted hazard ratio [aHR], 1.55 [95% CI, 1.17-2.05] per SD; P = .002), including aortic valve replacement (aHR, 2.22 [95% CI, 1.38-3.58] per SD; P = .001), after multivariable adjustment. The corrected LDL-C concentration was not significantly associated with AS events (aHR, 1.23 [95% CI, 0.93-1.61] per SD; P = .14). The overall HR for AS events with evolocumab was 0.66 (95% CI, 0.40-1.09), with no apparent association in the first year (HR, 1.09 [95% CI, 0.48-2.47]) but an HR of 0.48 (95% CI, 0.25-0.93) after the first year of treatment. Conclusions and Relevance: In this exploratory analysis of the FOURIER trial, higher Lp(a) levels, but not Lp(a)-corrected LDL-C levels, were associated with a higher risk of subsequent AS events, including aortic valve replacement. Long-term therapy with evolocumab may reduce AS events, and this raises the possibility that specific pharmacologic lipid-lowering therapy could offer a means to prevent or slow the progression of AS. These exploratory findings merit further investigation with a dedicated randomized clinical trial. Trial Registration: ClinicalTrials.gov Identifier: NCT01764633.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012543
003      
CZ-PrNML
005      
20210507103016.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1001/jamacardio.2020.0728 $2 doi
035    __
$a (PubMed)32347887
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bergmark, Brian A $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
245    13
$a An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial / $c BA. Bergmark, ML. O'Donoghue, SA. Murphy, JF. Kuder, MV. Ezhov, R. Ceška, I. Gouni-Berthold, HK. Jensen, SL. Tokgozoglu, F. Mach, K. Huber, Z. Gaciong, BS. Lewis, F. Schiele, JW. Jukema, TR. Pedersen, RP. Giugliano, MS. Sabatine
520    9_
$a Importance: Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a life-threatening condition with no proven disease-modifying therapy. Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) have been implicated in the pathobiology of AS. The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab reduces circulating LDL-C concentrations by 50% to 60% and Lp(a) by 20% to 30%. Objective: To determine whether evolocumab reduces the risk of AS events in patients with atherosclerotic cardiovascular disease. Interventions: Patients were randomized 1:1 to evolocumab or placebo. Design, Setting, and Participants: Exploratory analysis of the FOURIER trial, which enrolled 27 564 patients with stable atherosclerotic cardiovascular disease who were taking statin therapy at 1242 sites in 49 countries from February 2013 to November 2016. Patients were randomized to evolocumab or placebo and followed up for a median (interquartile range) of 2.2 (1.8-2.5) years. This post hoc analysis was performed from September 2019 to February 2020. Main Outcomes and Measures: Site-reported adverse events of new or worsening AS or aortic valve replacement (termed AS events). The adjusted risk of AS events was calculated with a multivariable model including concentrations of Lp(a) and LDL-C corrected for Lp(a) content, plus age, sex, diabetes, hypertension, current smoking, and estimated glomerular filtration rate. Evolocumab efficacy was tested using a Cox proportional hazards model. Results: Aortic stenosis events occurred in 63 patients (48 men [76%]; mean [SD] age, 69 [9] years) over a median of 2.2 years. Elevated Lp(a) concentration was associated with higher rates of AS events (adjusted hazard ratio [aHR], 1.55 [95% CI, 1.17-2.05] per SD; P = .002), including aortic valve replacement (aHR, 2.22 [95% CI, 1.38-3.58] per SD; P = .001), after multivariable adjustment. The corrected LDL-C concentration was not significantly associated with AS events (aHR, 1.23 [95% CI, 0.93-1.61] per SD; P = .14). The overall HR for AS events with evolocumab was 0.66 (95% CI, 0.40-1.09), with no apparent association in the first year (HR, 1.09 [95% CI, 0.48-2.47]) but an HR of 0.48 (95% CI, 0.25-0.93) after the first year of treatment. Conclusions and Relevance: In this exploratory analysis of the FOURIER trial, higher Lp(a) levels, but not Lp(a)-corrected LDL-C levels, were associated with a higher risk of subsequent AS events, including aortic valve replacement. Long-term therapy with evolocumab may reduce AS events, and this raises the possibility that specific pharmacologic lipid-lowering therapy could offer a means to prevent or slow the progression of AS. These exploratory findings merit further investigation with a dedicated randomized clinical trial. Trial Registration: ClinicalTrials.gov Identifier: NCT01764633.
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a anticholesteremika $x terapeutické užití $7 D000924
650    _2
$a aortální stenóza $x krev $x farmakoterapie $7 D001024
650    _2
$a LDL-cholesterol $x krev $7 D008078
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a proproteinkonvertasa subtilisin/kexin typu 9 $7 D000071449
650    _2
$a rizikové faktory $7 D012307
650    _2
$a subtilisin $x terapeutické užití $7 D020860
650    _2
$a výsledek terapie $7 D016896
650    _2
$a PCSK9 inhibitory $7 D000091362
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a O'Donoghue, Michelle L $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
700    1_
$a Murphy, Sabina A $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
700    1_
$a Kuder, Julia F $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
700    1_
$a Ezhov, Marat V $u National Medical Research Center of Cardiology, Moscow, Russia
700    1_
$a Ceška, Richard $u Third Internal Medicine Clinic, Center for Preventive Cardiology, University General Hospital, First Medical Faculty, Charles University, Prague, Czech Republic
700    1_
$a Gouni-Berthold, Ioanna $u Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany
700    1_
$a Jensen, Henrik K $u Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark $u Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark
700    1_
$a Tokgozoglu, S Lale $u Department of Cardiology, Hacettepe University, Ankara, Turkey
700    1_
$a Mach, François $u Cardiology Division, Geneva University Hospitals, Geneva, Switzerland
700    1_
$a Huber, Kurt $u Cardiology and Intensive Care Medicine, Wilhelminenhospital, Third Department of Medicine, Sigmund Freud University, Medical Faculty, Vienna, Austria
700    1_
$a Gaciong, Zbigniew $u Department of Internal Medicine, Hypertension and Vascular Disease, the Medical University of Warsaw, Warsaw, Poland
700    1_
$a Lewis, Basil S $u The Ruth and Bruce Rappaport School of Medicine, Lady Davis Carmel Medical Center, Technion-IIT, Haifa, Israel
700    1_
$a Schiele, Francois $u University Hospital Center Besançon, Besançon, France
700    1_
$a Jukema, J Wouter $u Department of Cardiology, Leiden University Medical Center, the Netherlands $u Netherlands Heart Institute, Utrecht, the Netherlands
700    1_
$a Pedersen, Terje R $u Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway
700    1_
$a Giugliano, Robert P $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
700    1_
$a Sabatine, Marc S $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
773    0_
$w MED00191356 $t JAMA cardiology $x 2380-6591 $g Roč. 5, č. 6 (2020), s. 709-713
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32347887 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103015 $b ABA008
999    __
$a ok $b bmc $g 1650832 $s 1132922
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 5 $c 6 $d 709-713 $e 20200601 $i 2380-6591 $m JAMA cardiology $n JAMA Cardiol $x MED00191356
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options